 "Natco Pharma hits new high on getting Establishment Inspection Report for Chennai facility")
Natco Pharma has surged 7% to hit fresh lifetime high of Rs 703 on the National Stock Exchange (NSE) after the drug maker announced receipt of successful Establishment Inspection Report (EIR) for Chennai facility.
“The company is pleased to announce receipt of successful Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the inspection conducted, during the period February 8 – February 12, 2016, at its chemical division, Chennai, India (named NATCO Organics Limited, prior to amalgamation into the company),” Natco Pharma said in a press release.
Last week, on August 16, Natco Pharma said the successful EIR from the USFDA for the inspection conducted at its drug manufacturing facility in Kothur village, Mahaboob Nagar district, India, during the period February 29 – March 7, 2016.
“The company is pleased to announce receipt of successful Establishment Inspection Report (EIR) from the U.S. Food and Drug Administration (FDA) for the inspection conducted, during the period February 8 – February 12, 2016, at its chemical division, Chennai, India (named NATCO Organics Limited, prior to amalgamation into the company),” Natco Pharma said in a press release.
Last week, on August 16, Natco Pharma said the successful EIR from the USFDA for the inspection conducted at its drug manufacturing facility in Kothur village, Mahaboob Nagar district, India, during the period February 29 – March 7, 2016.
The Kothur facility predominantly caters to regulated international markets, including USA.
The trading volumes on the counter jumped an over three-fold with a combined 938,841 shares changed hands on the BSE and NSE till 09:49 am.
The trading volumes on the counter jumped an over three-fold with a combined 938,841 shares changed hands on the BSE and NSE till 09:49 am.
